A23V2400/143

COMPOSITIONS AND METHODS OF USE OF NOVEL STRAINS OF LACTOBACILLUS FERMENTUM

Provided herein are novel Lactobacillus fermentum strains, NRRL B-67059 or NRRL B-67060, compositions containing the NRRL B-67059 or NRRL B-67060 strains, and fermented dairy products and bioactive compounds prepared using the NRRL B-67059 or NRRL B-67060 strains. Also provided are methods of modulating the immune system of a subject.

LACTIC BACTERIUM FOR TEXTURIZING FOOD PRODUCTS SELECTED ON THE BASIS OF PHAGE RESISTANCE

The present invention relates to a bacterial cell with texturizing property, starter cultures comprising the cell, and dairy products fermented with the starter culture.

Probiotics and fermentation metabolites for the prevention and treatment of disease conditions in animals
12257275 · 2025-03-25 · ·

The present invention is directed to compositions comprising a mixture of microbes and the metabolites produced when the microbes are grown together. The invention is further directed to methods for making and using the compositions.

Probiotics and fermentation metabolites for the prevention and treatment of disease conditions in animals
12257275 · 2025-03-25 · ·

The present invention is directed to compositions comprising a mixture of microbes and the metabolites produced when the microbes are grown together. The invention is further directed to methods for making and using the compositions.

FREEZE-DRIED PROBIOTIC FOODSTUFFS
20250113853 · 2025-04-10 ·

Compositions wherein foodstuffs act as carriers of freeze-dried probiotics provide new means for administration of probiotics. The products that are easily shipped may be eaten as purchased or mixed with other ingredients to provide variety in the diet while administering beneficial probiotic organisms to the gastrointestinal tract.

Mixture of lactic bacteria for the preparation of gluten free baked products

The present invention concerns a mixture of lactic bacteria for yeasting of gluten-free baked products. Particularly, the invention concerns the use of natural yeast based on selected lactic bacteria as yeasting agent for the production of gluten-free bread, with improved sensory and nutritional property, designed for celiac patients feeding.

Lactic bacterium for texturizing food products selected on the basis of phage resistance

The present invention relates to a bacterial cell with texturizing property, starter cultures comprising the cell, and dairy products fermented with the starter culture.

Materials and Methods for Improving Immune Responses and Skin and/or Mucosal Barrier Functions
20170020139 · 2017-01-26 ·

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.

Probiotic for inhibiting growth of <i>Proteus mirabilis</i>, and fermentation broth and application thereof

A probiotic for inhibiting growth of Proteus mirabilis, including a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof. A fermentation broth and an application of the probiotic are further provided.

Strain of lactobacillus fermentum capable of preventing and/or treating periodontitis and application

The present disclosure discloses a strain of Lactobacillus fermentum capable of preventing and/or treating periodontitis and an application thereof, belonging to the field of microbiology technology. The present disclosure has screened to obtain a strain of L. fermentum CCFM1139. The L. fermentum CCFM1139 can alleviate periodontitis by inhibiting formation of mixed bacterial biofilms of Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum, thereby reducing the amount of biofilm by 52.45%, and can reduce the content of TNF- from 131.37 pg/mL to 83.31 pg/mL and IL-8 from 147.70 pg/mL to 121.12 pg/mL in a periodontitis cell model, reduce colonization of the P. gingivalis and the F. nucleatum in the oral cavity by 1-2 orders of magnitude, and reduce the amount of the alveolar bone resorption from 1838.0 m to 805.7 m.